Onyx Pharmaceuticals and Multiple Myeloma Research Foundation Launch Carfilzomib Expanded Access Program

Onyx Pharmaceuticals, Inc. ONXX and the Multiple Myeloma Research Foundation today announced the initiation of an expanded access program for carfilzomib, a selective, next-generation proteasome inhibitor. The Carfilzomib Myeloma Access Program will include eligible patients in the United States with relapsed and refractory multiple myeloma. Expanded access programs make investigational medicines still being evaluated in clinical trials available to patients for whom no satisfactory treatment alternatives are available. The C-MAP protocol has been reviewed by the U.S. Food and Drug Administration and the company has received authorization to initiate the study.